Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Bihl, Florian ^a   Russmann, Stefan ^b   Gurtner, Vanina ^c   Di Giammarino, Loriana ^a   Pizzi Bosman, Loredana ^a   Michel, Martine ^a   Cerny, Andreas ^d   Hadengue, Antoine ^a   Majno, Pietro ^a   Giostra, Emiliano ^a   Castelli, Damiano ^c   Mentha, Gilles ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Red Cross Blood Transfusion Service of Southern Switzerland   (Switzerland)

^d Reparto di Chirurgia Ortopedica   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CLEMASTINE; HYPERIMMUNE GLOBULIN; LAMIVUDINE; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HOT FLUSH; HUMAN; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRURITUS; RECURRENT DISEASE; DRUG COMBINATION; ECONOMICS; IMMUNOLOGY; MIDDLE AGED; PLASMA; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA; RECURRENCE; TREATMENT OUTCOME;

EID: 77955347761     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-71     Document Type: Article

References (28)

1. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005, 11:716-32. 10.1002/lt.20492, 15973718.
2. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007, 14(Suppl 1):37-44. 10.1111/j.1365-2893.2007.00916.x, 17958641.
3. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998, 28:585-9. 10.1002/hep.510280241, 9696028.
4. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008, 14:435-42. 10.1002/lt.21343, 18383078.
5. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002, 8:S67-73. 10.1053/jlts.2002.35780, 12362302.
6. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004, 10:S74-85. 10.1002/lt.20258, 15382222.
7. Villamil FG. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J Hepatol 2003, 39:466-74. 10.1016/S0168-8278(03)00396-9, 12971953.
8. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen?. Liver Transpl 2008, 14(Suppl 2):S15-22.
9. Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives?. Liver Transpl 2008, 14(Suppl 2):S23-6.
10. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000, 32:1189-95. 10.1053/jhep.2000.19789, 11093723.
11. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004, 77:1203-8. 10.1097/01.TP.0000118904.63669.EB, 15114086.
12. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007, 13:374-81. 10.1002/lt.21041, 17318855.
13. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001, 34:888-94. 10.1016/S0168-8278(01)00039-3, 11451173.
14. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006, 12:253-8. 10.1002/lt.20701, 16447195.
15. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-6. 10.1002/hep.22524, 18925641.
16. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000, 6:429-33. 10.1053/jlts.2000.8310, 10915163.
17. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007, 132:931-7. 10.1053/j.gastro.2007.01.005, 17383422.
18. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004, 36:535-8. 10.1016/j.transproceed.2004.02.025, 15110584.
19. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329:1842-7. 10.1056/NEJM199312163292503, 8247035.
20. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003, 38:86-95. 10.1053/jhep.2003.50294, 12829990.
21. McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant 2000, 14(Suppl 2):29-38.
22. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000, 6:741-8. 10.1053/jlts.2000.18702, 11084061.
23. Terrault N. Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges. Clin Transplant 2000, 14(Suppl 2):39-43.
24. Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation. Clin Liver Dis 2003, 7:537-50. 10.1016/S1089-3261(03)00045-X, 14509525.
25. Mentha G, Giostra E, Negro F, Rubbia-Brandt L, Huber O, Hadengue A, et al. High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation. Transplant Proc 1997, 29:2369-73. 10.1016/S0041-1345(97)00407-7, 9270768.
26. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002, 16:61-6. 10.1053/tmrv.2002.29405, 11788930.
27. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. J Transl Med 2007, 5:25. 10.1186/1479-5876-5-25, 1904179, 17553144.
28. Adler R, Safadi R, Caraco Y, Rowe M, Etzioni A, Ashur Y, et al. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999, 29:1299-305. 10.1002/hep.510290446, 10094978.